{
  "question_stem": {
    "en": "A 67-year-old man with nonischemic cardiomyopathy comes to the office for follow-up. He recently was hospitalized for acute decompensated heart failure. The patient's symptoms have improved with multidrug treatment, but he has persistent shortness of breath on mild exertion. He has a history of hypertension and hypercholesterolemia. Blood pressure is 115/70 mm Hg and pulse is 66/min. There is a third heart sound on heart auscultation and mild lower extremity pitting edema. A recent echocardiogram showed a left ventricular ejection fraction of 30%.",
    "zh": "一名67岁男性，患有非缺血性心肌病，前来复诊。他近期因急性失代偿性心力衰竭住院。患者的症状通过多药治疗有所改善，但在轻微活动时仍有持续性呼吸困难。他有高血压和高胆固醇血症病史。血压115/70 mmHg，脉搏66次/分钟。心脏听诊有第三心音，轻度下肢凹陷性水肿。最近的心脏超声显示左室射血分数30%。"
  },
  "question": {
    "en": "Which of the following diuretics would most likely improve survival if added to this patient's current regimen?",
    "zh": "如果在此患者目前的治疗方案中加入以下哪种利尿剂，最有可能改善生存率？"
  },
  "options": {
    "A": {
      "en": "Acetazolamide",
      "zh": "乙酰唑胺"
    },
    "B": {
      "en": "Furosemide",
      "zh": "呋塞米"
    },
    "C": {
      "en": "Hydrochlorothiazide",
      "zh": "氢氯噻嗪"
    },
    "D": {
      "en": "Mannitol",
      "zh": "甘露醇"
    },
    "E": {
      "en": "Spironolactone",
      "zh": "螺内酯"
    },
    "F": {
      "en": "Triamterene",
      "zh": "氨苯蝶啶"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "Mineralocorticoid receptor antagonists (eg, spironolactone, eplerenone) prevent aldosterone from binding to its receptor in the distal renal tubules. This leads to increased sodium and water excretion while conserving potassium ions (potassium-sparing diuresis). These antagonists also block the deleterious effect of aldosterone on the heart, causing regression of myocardial fibrosis and improvement in ventricular remodeling.\n\nMineralocorticoid receptor antagonists reduce morbidity and improve survival in patients with congestive heart failure and decreased ejection fraction. Therefore, they are recommended in addition to standard heart failure therapy (ACE inhibitors and beta blockers). They should not be used in patients with hyperkalemia or renal failure. The most common side effects are hyperkalemia and gynecomastia (spironolactone >> eplerenone).\n\n(Choices A, C, and F) Acetazolamide (carbonic anhydrase inhibitor), hydrochlorothiazide (thiazide diuretic), and triamterene (epithelial sodium channel blocker) have a variably lower diuretic effect compared to loop diuretics and are not as efficacious for treating heart failure symptoms.\n\n(Choice B) Furosemide is a loop diuretic frequently used for treatment of pulmonary congestion and fluid retention in heart failure patients. Although loop diuretics improve symptoms significantly, they do not provide survival benefit (ie, improved morbidity but not mortality) in these patients.\n\n(Choice D) Mannitol is an intravenous osmotic diuretic used primarily to lower intracranial pressure and treat acute glaucoma. It is not used to treat heart failure as it can cause an initial rise in extracellular fluid volume, exacerbating pulmonary congestion and peripheral fluid retention.\n\nEducational objective:\nMineralocorticoid receptor antagonists (eg, spironolactone, eplerenone) improve survival in patients with congestive heart failure and reduced left ventricular ejection fraction. They should not be used in patients with hyperkalemia or renal failure.",
    "zh": "盐皮质激素受体拮抗剂（如螺内酯、依普利酮）可阻止醛固酮与其在远端肾小管中的受体结合。这会导致钠和水的排泄增加，同时保留钾离子（保钾利尿）。这些拮抗剂还可阻断醛固酮对心脏的有害影响，导致心肌纤维化消退和心室重塑改善。\n\n盐皮质激素受体拮抗剂可降低充血性心力衰竭和射血分数降低患者的发病率，并提高其生存率。因此，建议在标准的心力衰竭治疗（ACE抑制剂和β受体阻滞剂）的基础上加用此类药物。对于高钾血症或肾功能衰竭的患者，不应使用此类药物。最常见的副作用是高钾血症和男性乳房发育症（螺内酯 >> 依普利酮）。\n\n（选项A、C和F）乙酰唑胺（碳酸酐酶抑制剂）、氢氯噻嗪（噻嗪类利尿剂）和氨苯蝶啶（上皮钠通道阻滞剂）的利尿作用与袢利尿剂相比变化不定且较低，对治疗心力衰竭症状的疗效也不如袢利尿剂。\n\n（选项B）呋塞米是一种袢利尿剂，常用于治疗心力衰竭患者的肺充血和液体潴留。虽然袢利尿剂可显著改善症状，但不能为这些患者提供生存获益（即改善发病率，但不能降低死亡率）。\n\n（选项D）甘露醇是一种静脉注射渗透性利尿剂，主要用于降低颅内压和治疗急性青光眼。它不用于治疗心力衰竭，因为它会导致细胞外液容量的初步升高，从而加剧肺充血和周围水肿。\n\n教学目标：\n盐皮质激素受体拮抗剂（如螺内酯、依普利酮）可提高充血性心力衰竭和左室射血分数降低患者的生存率。对于高钾血症或肾功能衰竭的患者，不应使用此类药物。"
  },
  "summary": {
    "en": "This question tests knowledge of heart failure management, specifically the role of mineralocorticoid receptor antagonists in improving survival in patients with heart failure and reduced ejection fraction.\n\nThe best approach is to recognize the patient's heart failure with reduced ejection fraction and identify the diuretic that has been shown to improve survival in this population, which is a mineralocorticoid receptor antagonist like spironolactone.",
    "zh": "本题考察对心力衰竭管理的知识，特别是盐皮质激素受体拮抗剂在改善心力衰竭和射血分数降低患者生存率方面的作用。\n\n最好的方法是识别患者的射血分数降低的心力衰竭，并确定已被证明可改善该人群生存率的利尿剂，即螺内酯等盐皮质激素受体拮抗剂。"
  },
  "tags": "Heart failure; Reduced ejection fraction; Mineralocorticoid receptor antagonists; Spironolactone; Diuretics; Cardiology",
  "category": "CVS",
  "question_id": "686",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\686",
  "extracted_at": "2025-11-05T12:15:15.548399",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:30:43.721003",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}